Lupin has provided an update on its acquisition timeline for Amsterdam-based VISUfarma BV, indicating the transaction is now expected to close by February 28, 2026, subject to certain closing conditions. The pharmaceutical company had originally indicated the acquisition would be completed by the end of calendar year 2025. This development comes alongside the company's recent strategic partnership announcement for GLP-1 drug commercialization in India.

VISUfarma Acquisition Update

The company recalled that Nanomi BV, its wholly-owned subsidiary, had entered into a definitive agreement on September 29, 2025, to acquire the entire share capital of VISUfarma BV. The acquisition represents part of Lupin's broader expansion strategy, though specific financial terms and strategic rationale for the VISUfarma deal have not been disclosed.

GLP-1 Drug Partnership Reinforced

Simultaneously, Lupin has reaffirmed its exclusive licensing, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist. This strategic partnership strengthens Lupin's diabetes portfolio while expanding its presence in the obesity treatment segment for the Indian market.

Bofanglutide injection is designed for adults with type 2 diabetes and assists in weight management for overweight or obese individuals. As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that weight loss results are comparable to or better than existing GLP-1 alternatives while offering enhanced convenience through reduced injection frequency.

Market Opportunity and Health Impact

The GLP-1 partnership addresses significant health challenges in India, where obesity is anticipated to develop into a major health crisis. The market opportunity remains substantial, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes already affects approximately 90 million adults in the country, representing an epidemic-level health concern.

Current Stock Performance

Shares of Lupin ended at ₹2,080.40, declining by ₹1.70 or 0.08% during the latest trading session. The stock has faced broader challenges with a year-to-date decline of 12.00%, though the strategic partnerships in high-growth therapeutic areas are expected to draw continued investor attention.

Lupin has announced a strategic partnership with Neopharmed for the exclusive licensing of Plasil, a gastroenterology drug, in the Philippines and Brazil markets. This collaboration marks another step in Lupin's international expansion strategy through targeted licensing agreements.

Partnership Details

The exclusive licensing agreement grants specific rights for Plasil distribution and marketing in two key emerging markets. The partnership structure leverages Neopharmed's regional expertise and established distribution networks in both countries.

Market Expansion Strategy

This licensing agreement represents Lupin's focused approach to international market penetration through strategic partnerships. The collaboration allows the company to access established distribution channels and regulatory expertise in both the Philippines and Brazil markets.

The partnership with Neopharmed provides Lupin with access to two significant markets in different geographical regions, potentially expanding the reach of Plasil in the gastroenterology therapeutic segment.

Strategic Implications

The exclusive licensing arrangement enables Lupin to expand its gastroenterology portfolio presence internationally while partnering with a company that has established market knowledge and distribution capabilities. This approach allows for market entry with reduced operational complexity and leverages local expertise for regulatory and commercial success.

This strategic move aligns with Lupin's broader goal of expanding its international presence. By partnering with Neopharmed, Lupin aims to strengthen its position in the gastroenterology market in the Philippines and Brazil, leveraging local expertise to enhance its market penetration and product reach.